The Genitourinary Drugs Global Market Is Expected To Grow Close To $82 Billion By 2021 According To TBRC’s Latest Report

The genitourinary drugs market covers drugs that are used in the treatment of diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, renovascular diseases, benign prostate diseases, and other related diseases.

Read the report at

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report-2018

The major reason why the global genitourinary drugs market will increase from $63 billion in 2017 to close to $82 billion by 2021 is growth of genitourinary disorders like chronic kidney disease CKD and the number of pipeline drugs.

In the report, the global genitourinary drugs market is divided into eight segments namely, hormonal contraceptives, drugs for hormonal replacement therapy, drugs for infections and others, drugs for benign prostatic hypertrophy, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infertility, and diuretics. While the first and the second segments account for nearly three-fifth of the market share, the remaining share is attributed to the other six segments.

Download a sample of the report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=253&type=smp

The USA was the largest country in the genitourinary drugs market in 2017, accounting for around 30% of the market share. This can be attributed to the high prevalence of urinary diseases like chronic kidney diseases, erectile dysfunction and infertility in the country. Moreover, public awareness and expenditure on health care is high in the USA. China and Italy followed the USA as the next largest countries in the market.

The genitourinary drugs market is fragmented with a number of large and small drugs organizations. The top five competitors in the market made up 14% of the total market in 2017. Daiichi Sankyo Company, Limited was the largest competitor of the market, followed by Pfizer Inc. and Bayer AG. Daiichi Sankyo Company is involved in the research, development and marketing of pharmaceutical products for osteoporosis, ulcer treatment, alzheimer’s disease, anti-influenza treatment, hypertension and diabetes. The company is headquartered in Tokyo, Japan and employs 14,670 people.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.